A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

November 10, 2027

Study Completion Date

July 10, 2028

Conditions
Neoplasms
Interventions
DRUG

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy

Dabrafenib 150 mg twice orally daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks, Сalcium folinate 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks.

Trial Locations (1)

115193

RECRUITING

Blokhin's Russian Cancer Research Center, Moscow

All Listed Sponsors
collaborator

City Clinical Oncology Hospital No 1

OTHER_GOV

collaborator

Moscow City Oncology Hospital No. 62

OTHER_GOV

collaborator

The Loginov MCSC MHD

UNKNOWN

collaborator

MMCC Kommunarka MHD

UNKNOWN

lead

Blokhin's Russian Cancer Research Center

OTHER